Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theralase Technologies's Enterprise Value is C$39.83 Mil.
Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-3.39 Mil. Therefore, Theralase Technologies's EV-to-EBIT ratio for today is -11.74.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Theralase Technologies's Enterprise Value is C$39.83 Mil.
Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-3.25 Mil. Therefore, Theralase Technologies's EV-to-EBITDA ratio for today is -12.25.
Theralase Technologies Enterprise Value Historical Data
The historical data trend for Theralase Technologies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Theralase Technologies's Enterprise Value
For the Medical Devices subindustry, Theralase Technologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Enterprise Value falls into.
Theralase Technologies Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Theralase Technologies's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TSXV:TLT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Theralase Technologies's current Enterprise Value is C$39.83 Mil.
Theralase Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.39 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Theralase Technologies's EV-to-EBITDA for today is:
Theralase Technologies's current Enterprise Value is C$39.83 Mil.
Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.25 Mil.
Theralase Technologies's current Enterprise Value is C$39.83 Mil.
Theralase Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies Enterprise Value Related Terms
Thank you for viewing the detailed overview of Theralase Technologies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Theralase Technologies (TSXV:TLT) Business Description
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:TLT has been successfully added to your 